Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Cocrystal Pharma ( (COCP) ) has provided an announcement.
On October 27, 2025, Cocrystal Pharma announced it received a Small Business Innovation Research Phase I award from the NIH and NIAID to support the development of a novel oral antiviral candidate for influenza A and B. This $500,000 award will help advance their influenza inhibitor program, potentially leading to further funding opportunities and strengthening their position in antiviral drug development.
The most recent analyst rating on (COCP) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Cocrystal Pharma stock, see the COCP Stock Forecast page.
Spark’s Take on COCP Stock
According to Spark, TipRanks’ AI Analyst, COCP is a Underperform.
Cocrystal Pharma faces significant financial challenges, with no revenue and ongoing operational losses severely affecting its stock score. The technical analysis indicates potential downward pressure, while the negative valuation metrics are concerning. However, recent corporate events provide some positive aspects, suggesting future growth potential. Overall, the company’s stock score reflects these mixed factors, indicating substantial risk with some long-term opportunities.
To see Spark’s full report on COCP stock, click here.
More about Cocrystal Pharma
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company focused on discovering and developing novel antiviral therapeutics targeting the replication process of influenza viruses, coronaviruses, noroviruses, and hepatitis C viruses. The company employs unique structure-based technologies to create viable antiviral drugs.
Average Trading Volume: 1,535,833
Technical Sentiment Signal: Sell
Current Market Cap: $15.39M
See more data about COCP stock on TipRanks’ Stock Analysis page.